FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
Based on these metrics, Johnson & Johnson broadened the way patients can access the enrolment channels beyond the initial pilot funnel in mid-January 2026, reflecting continued confidence in the programme’s performance.
The collaboration was initially signed in January 2025, has been extended to mid-2026 with the same economic terms, including a fixed monthly management fee.
Trellus Health also continues to move forward with its TrialSet vertical, which is being deployed into agreed-upon sites with ICON plc(NASDAQ:ICLR) for an ongoing, mid-stage immunology and inflammation clinical trial sponsored by Takeda Pharmaceutical Co Ltd(NYSE:TAK).
See Also: Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In at $0.85/Share
Trellus is also implementing TrialSet with PSI Inc. across two late-stage immunology and inflammation clinical trials sponsored by Sanofi SA(NASDAQ:SNY) and will be deployed into agreed-upon sites beginning mid of the second quarter.
“We are establishing a scalable go-to-market model for pharma, with continued focus on disciplined execution, recurring revenue growth, and expansion across immunology and inflammation. We look forward to updating the market on further developments,” commented Marla Dubinsky, CEO and Co-founder of Trellus Health.
Funding and Outlook
As previously disclosed, Trellus Health expects fiscal 2025 revenue to be approximately $545 thousand and has further reduced its monthly cash burn to around $400 thousand by late 2025 from around $440 thousand in October 2025.
This was moderately offset by recurring monthly management fees generated during the second half of the year.
Read Next: This Under-$1 Pre-IPO AI Company Is Still Open to Retail Investors — Learn More
Image via Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga:
This article FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer originally appeared on Benzinga.com
Content Original Link:
" target="_blank">
